Overview

DV Combined With PD-1 and Platinum-based First-line Treatment in Patients With HER2 IHC2+/3+ ESCC

Status:
Not yet recruiting
Trial end date:
2025-04-30
Target enrollment:
Participant gender:
Summary
This is a single-arm, exploratory clinical study.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Changhai Hospital
Treatments:
Disitamab vedotin